Litcius/Paper detail

The CONUT score is prognostic in esophageal cancer treated with chemoradiotherapy

Metin Demir, Nazım Can Demircan

2022Saudi Journal of Gastroenterology11 citationsDOIOpen Access PDF

Abstract

Background: Malnutrition is a frequent issue in esophageal cancer (EC). The Controlling Nutritional Status (CONUT) Score has been established as a prognostic indicator in EC patients who underwent surgery. We aimed to investigate the role of the CONUT Score in EC patients treated with chemoradiotherapy (CRT). Methods: The trial included 101 non-metastatic EC patients. Receiver operating characteristic (ROC) curve analyses were used to determine cut-off values for the CONUT Score and other indices. Cox regression analyses were performed to determine prognostic markers. Results: Of 101 patients, 59.4% (n = 60) and 40.6% (n = 41) of patients were treated with CRT alone and CRT plus surgery, respectively. ROC curve analyses determined an optimal cut-off for CONUT Score in overall survival (OS), which was 3.5 (AUC = 0.63, CI 95%: 0.51-0.76, P = 0.05). The sensitivity and specificity of CONUT were 66% and 61%, respectively. Low CONUT (≤3.5) patients had significantly longer median OS than high CONUT (>3.5) patients (57.1 vs. 23 months; P = 0.009). Multivariate regression analysis revealed a CONUT Score hazard ratio (HR) of 1.96 for OS (CI 95%: 1.03-3.75, P = 0.04). Conclusion: The CONUT Score might be a useful prognostic tool in EC patients treated with CRT. Appropriate nutritional support might provide a better prognosis, which underlines the importance of multidisciplinary assessment of malnutrition in EC patients.

Topics & Concepts

MedicineReceiver operating characteristicInternal medicineHazard ratioEsophageal cancerProportional hazards modelChemoradiotherapyMultivariate analysisGastroenterologyOncologyCancerConfidence intervalNutrition and Health in AgingInflammatory Biomarkers in Disease PrognosisEsophageal Cancer Research and Treatment
The CONUT score is prognostic in esophageal cancer treated with chemoradiotherapy | Litcius